Latest Neuroprotection Stories
Richard Borgens and his colleagues from the Center for Paralysis Research at the Purdue School of Veterinary Medicine have a strong record of inventing therapies for treating nerve damage.
The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing.
HERZLIYA PITUACH, Israel, February 9 /PRNewswire/ -- SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM).
Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.
NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- As part of its mission to speed development of transformative treatments for Parkinson's disease, The Michael J.
Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.
NEW YORK, Dec. 10 /PRNewswire-USNewswire/ -- As part of its mission to accelerate promising therapeutic targets through the development pipeline toward clinical trials and, ultimately, patient care, The Michael J.
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease â€“ findings that could point the way to a new type of therapy.
JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program.
- A political dynamiter.